Journal
ENDOCRINE-RELATED CANCER
Volume 22, Issue 1, Pages T35-T54Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-14-0516
Keywords
deubiquitinases; USP7; USP22; CYLD; UCHL1; BAP1; A20; ataxin 3
Categories
Funding
- Canadian Institutes of Health Research (CIHR) [106583]
Ask authors/readers for more resources
Deubiquitinases (DUBs) play important roles and therefore are potential drug targets in various diseases including cancer and neurodegeneration. In this review, we recapitulate structure-function studies of the most studied DUBs including USP7, USP22, CYLD, UCHL1, BAP1, A20, as well as ataxin 3 and connect them to regulatory mechanisms and their growing protein interaction networks. We then describe DUBs that have been associated with endocrine carcinogenesis with a focus on prostate, ovarian, and thyroid cancer, pheochromocytoma, and adrenocortical carcinoma. The goal is enhancing our understanding of the connection between dysregulated DUBs and cancer to permit the design of therapeutics and to establish biomarkers that could be used in diagnosis and prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available